Factor VIII — Drug Target
All drugs that target Factor VIII — marketed and clinical-stage. Includes 5 drug classes acting on this target.
Drug classes
Coagulation factor replacement therapy · recombinant factor VIII replacement therapy · Factor VIII replacement therapy · Coagulation factor replacement · Coagulation factor VIII replacement therapy
Phase 3 pipeline (4)
- human VWF/FVIII concentrate · Octapharma · Coagulation factor replacement therapy · Hematology
Human VWF/FVIII concentrate replaces clotting factors in the blood to prevent or control bleeding episodes in patients with hemophilia A. - rFVIII (BAY81-8973) on demand · Bayer · recombinant factor VIII replacement therapy · Hematology
rFVIII (BAY81-8973) is a recombinant factor VIII replacement therapy that mimics the natural protein to treat bleeding episodes in patients with hemophilia A. - rIX-FP · CSL Behring · Factor VIII replacement therapy · Hematology
rIX-FP is a recombinant, humanized monoclonal antibody that targets factor VIII to prevent bleeding in patients with hemophilia A. - PEGylated Recombinant Factor VIII · Baxalta now part of Shire · Factor VIII replacement therapy · Hemophilia A
PEGylated Recombinant Factor VIII is a recombinant form of human factor VIII that is modified with polyethylene glycol (PEG) to prolong its half-life.
Phase 2 pipeline (4)
- ADYNOVI · Baxalta now part of Shire · Factor VIII replacement therapy · Hematology
ADYNOVI is a recombinant human coagulation factor VIII, used to treat and prevent bleeding episodes in patients with hemophilia A. - FVIII Replacement · Hoffmann-La Roche · Coagulation factor replacement · Rare Disease
Recombinant FVIII replacement to correct FVIII deficiency - FVIII products · Bayer · Coagulation factor VIII replacement therapy · Hematology
FVIII products replace or supplement the missing or defective clotting factor VIII in the blood to help the blood to clot normally. - BAY14-2222_Kogenate-FS FVIII · Bayer · Factor VIII replacement therapy · Hematology
Factor VIII replacement therapy